CS Genetics

CS Genetics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

CS Genetics is a private, pre-revenue platform company pioneering a new approach to single-cell genomics. Its proprietary SimpleCell platform utilizes a novel biochemical method called Kinetic Confinement to perform single-cell indexing in standard labware, eliminating the need for complex microfluidics or proprietary hardware. The company aims to democratize single-cell analysis by reducing cost and complexity, thereby enabling larger-scale studies such as population genomics and accelerating discovery across basic research and drug development.

Genetics & Genomics

Technology Platform

SimpleCell platform utilizing Kinetic Confinement, a novel thermodynamic method for single-cell indexing in standard labware, powered by CPair bead reagents.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The growing demand for scalable, cost-effective single-cell analysis presents a major opportunity, especially for population-scale genomics and large cohort studies.
The hardware-agnostic, simple workflow can lower adoption barriers for a wider range of research labs and core facilities.

Risk Factors

Key risks include intense competition from established players with dominant market share, the challenge of proving platform performance and reliability at scale to drive adoption, and the execution risks associated with manufacturing, distribution, and scaling a commercial-stage tools company.

Competitive Landscape

CS Genetics competes in the single-cell analysis market dominated by integrated platform providers like 10x Genomics and BD, as well as other hardware-free approaches like those from Parse Biosciences (combinatorial indexing) and others. Its differentiation lies in the novel Kinetic Confinement chemistry promising simplicity and scalability in standard labware.